Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

Jillian M. PrendergastSiamab Therapeutics, Inc., Newton, MA, USACorrespondence[email protected]

Ana Paula Galvao da SilvaSiamab Therapeutics, Inc., Newton, MA, USA

David A. EavaroneSiamab Therapeutics, Inc., Newton, MA, USA

Darius GhaderiSiamab Therapeutics, Inc., Newton, MA, USA

Mai ZhangSiamab Therapeutics, Inc., Newton, MA, USA

Dane BradyAlizée Pathology, LLC, Thurmont, MD, USA

Joan WicksAlizée Pathology, LLC, Thurmont, MD, USA

Julie DeSanderSiamab Therapeutics, Inc., Newton, MA, USA

Jeff BehrensSiamab Therapeutics, Inc., Newton, MA, USA

Bo R. RuedaVincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USA

show all

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

Supplemental_Data.zip

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

Supplemental_Data.zip

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date